Editas Medicine, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-160.1M | $-237.1M | $-153.2M | $-220.4M | $-192.5M | $-116.0M | $-133.7M | $-110.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $5.3M | $5.8M | $6.1M | $6.3M | $5.1M | $4.0M | $2.8M | $3.3M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $10.0M | $21.4M | $19.8M | $29.3M | $43.4M | $23.2M | $27.2M | $26.6M |
| Net Cash from Operating Activities | $-165.2M | $-210.3M | $-132.2M | $-177.3M | $-163.8M | $-179.8M | $-40.7M | $-45.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $607.0K | $8.8M | $4.7M | $4.1M | $8.0M | $7.2M | $6.2M | $4.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $138.7M | $162.1M | $-3.7M | $114.1M | $-54.5M | $-140.5M | $12.3M | $-53.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $40.5M | $56.0M | $118.0M | $1.3M | $282.1M | $224.1M | $131.8M | $86.9M |
| Net Change in Cash | $13.9M | $7.9M | $-17.9M | $-62.0M | $63.8M | $-96.2M | $103.4M | $-11.9M |
| Free Cash Flow | $-165.8M | $-219.1M | $-136.9M | $-181.5M | $-171.8M | $-187.0M | $-46.8M | $-50.5M |